

## Special Issue

# Multigene Assays in Early Breast Cancer: Implications for Classification, Staging, Prognosis and Treatment

### Message from the Guest Editors

In the last 2 decades, a new conceptual approach to breast cancer (BC) has emerged, providing a better understanding of the biology of the disease. With the advent of genomic analyses, it has become evident the BC is not a single type of tumor, but a group of different diseases with distinct molecular properties, eventually defined by the use of multigene assays (MGAs). Each of these different molecular properties identifies different BC subtypes that tend to respond differently to the anti-cancer therapy. This fuelled the promise of MGAs to provide detailed and specific molecular information, which will ultimately lead to individualize a more precise BC treatment, along with a more accurate BC classification and staging. This Special Issue focuses on the role and impact of the different MGAs in eBC and their implications for classification, staging, prognosis and treatment. We cordially invite authors in the field to submit original research or review articles pertaining to this important and progressing field of biomedicine.

### Guest Editors

Dr. Alberto Zambelli

Medical Oncology Unit, Azienda Ospedaliera Papa Giovanni XXIII, 24127 Bergamo, Italy

Dr. Carlo Tondini

Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy

### Deadline for manuscript submissions

closed (31 October 2021)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/62089](https://mdpi.com/si/62089)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).